

NOV 18 2004

U.S. PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 3

APPLICATION NO.: 10/023,909

ATTY. DOCKET NO.: C1039.70058US00

FILING DATE: December 18, 2001

CONFIRMATION NO.: 8458

APPLICANT: Davis et al.

GROUP ART UNIT: 1648

EXAMINER: Jeffrey S. Parkin

Jeffrey

S. Parkin

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
	A52	4,578,269		Morein	03-25-1986
	A53	4,981,684		MacKenzie et al.	01-01-1991
	A54	5,178,860		MacKenzie et al.	01-12-1993
	A55	5,679,354		Morein et al.	10-21-1997
	A56	6,027,732		Morein et al.	02-22-2000
	A57	6,544,518	B1	Friede et al.	04-08-2003
	A58	6,558,670	B1	Friede et al.	05-06-2003
	A59	6,727,230	B1	Hutcherson et al.	04-27-2004
	A60	2001-0044416	A1	McCluskie et al.	11-22-2001
	A61	2002-0064515	A1	Krieg et al.	05-30-2002
	A62	2002-0091097	A1	Bratzler et al.	07-11-2002
	A63	2002-0164341	A1	Davis et al.	11-07-2002
	A64	2002-0165178	A1	Schetter et al.	11-07-2002
	A65	2002-0198165	A1	Bratzler et al.	12-26-2002
	A66	2003-0026782	A1	Krieg et al.	02-06-2003
	A67	2003-0026801	A1	Weiner et al.	02-06-2003
	A68	2003-0050261	A1	Krieg et al.	03-13-2003
	A69	2003-0050268	A1	Krieg et al.	03-13-2003
	A70	2003-0055014	A1	Bratzler	03-20-2003
	A71	2003-0087848	A1	Bratzler et al.	05-08-2003
	A72	2003-0091599	A1	Davis et al.	05-15-2003
	A73	2003-0100527	A1	Krieg et al.	05-29-2003
	A74	2003-0104523	A1	Bauer et al.	06-05-2003
	A75	2003-0139364	A1	Krieg et al.	07-24-2003
	A76	2003-0148316	A1	Lipford et al.	08-07-2003
	A77	2003-0148976	A1	Krieg et al.	08-07-2003
	A78	2003-0166001	A1	Lipford	09-04-2003
	A79	2003-0181406	A1	Schetter et al.	09-25-2003
	A80	2003-0191079	A1	Krieg et al.	10-09-2003
	A81	2003-0212026	A1	Krieg et al.	11-13-2003
	A82	2003-0224010	A1	Davis et al.	12-04-2003
	A83	2003-0232074	A1	Lipford et al.	12-18-2003
	A84	2004-0009944	A1	Tam et al.	01-15-2004
	A85	2004-0009949	A1	Krieg	01-15-2004
	A86	2004-0030118	A1	Wagner et al.	02-12-2004
	A87	2004-0038922	A1	Haensler et al.	02-26-2004
	A88	2004-0053880	A1	Krieg	03-18-2004
	A89	2004-0067905	A1	Krieg	04-08-2004
	A90	2004-0087534	A1	Krieg et al.	05-06-2004

<p style="text-align: center;">O'LEARY & JONES U.S. PATENT & TRADEMARK OFFICE</p> <p style="text-align: center;">NOV 18 2001</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p>		APPLICATION NO.: 10/023,909		ATTY. DOCKET NO.: C1039.70058US00		
		FILING DATE: December 18, 2001		CONFIRMATION NO.: 8458		
		APPLICANT: Davis et al.				
		GROUP ART UNIT: 1648		EXAMINER: <i>Jeffrey S. Parkin</i>		
Sheet	2	of	3			

8	A91	2004-0087538	A1	Krieg et al.	05-06-2004
1	A92	2004-0092472	A1	Krieg	05-13-2004
	A93	2004-0106568	A1	Krieg et al.	06-03-2004
	A94	2004-0131628	A1	Bratzler et al.	07-08-2004
	A95	2004-0132685	A1	Krieg et al.	07-08-2004
	A96	2004-0142469	A1	Krieg et al.	07-22-2004
	A97	2004-0143112	A1	Krieg et al.	07-22-2004
	A98	2004-0147468	A1	Krieg et al.	07-29-2004
	A99	2004-0152649	A1	Krieg	08-05-2004
	A100	2004-0152656	A1	Krieg et al.	08-05-2004
	A101	2004-0152657	A1	Krieg et al.	08-05-2004
	A102	2004-0162258	A1	Krieg et al.	08-19-2004
	A103	2004-0162262	A1	Krieg et al.	08-19-2004
	A104	2004-0167089	A1	Krieg et al.	08-26-2004
	A105	2004-0171150	A1	Krieg et al.	09-02-2004
	A106	2004-0171571	A1	Krieg et al.	09-02-2004
	A107	2004-0181045	A1	Krieg et al.	09-16-2004
↓	A108	2004-0198688	A1	Krieg et al.	10-07-2004

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
8	B15	EP	0 773 295	A2	Ottawa Civic Hospital	05-14-1997	
	B16	WO	98/52962	A1	Merck & Co., Inc.	11-26-1998	
	B17	WO	99/56755	A1	University of Iowa Research Foundation	11-11-1999	
	B18	WO	00/09159	A1	Aquila Biopharmaceuticals, Inc.	02-24-2000	
	B19	WO	00/15256	A2	Pasteur Merieux Serums et Vaccins	03-23-2000	Y - Abstract Only
	B20	WO	00/23105	A2	Smithkline Beecham Biologicals S.A.	04-27-2000	
	B21	WO	00/46365	A1	Virginia Commonwealth University	08-10-2000	
	B22	WO	00/62800	A2	Smithkline Beecham Biologicals S.A.	10-26-2000	
	B23	WO	02/28428	A2	Aventis Pasteur	04-11-2002	Y - Abstract Only
	B24	WO	03/026688	A1	Pharmaderm Laboratories, Ltd.	04-03-2003	
	B25	WO	2004/007743	A2	Coley Pharmaceutical GMBH	01-22-2004	
8	B26	WO	2004/039829	A2	Coley Pharmaceutical Group, Ltd.	05-13-2004	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
Sheet	3	f	3
APPLICATION NO.: 10/023,909		ATTY. DOCKET NO.: C1039.70058US00	
FILING DATE: December 18, 2001		CONFIRMATION NO.: 8458	
APPLICANT: Davis et al.			
GROUP ART UNIT: 1648		EXAMINER: <i>Jeffrey S. Parkin</i>	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C14	DASS et al., Immunostimulatory activity of cationic-lipid-nucleic-acid complexes against cancer. J Cancer Res Clin Oncol. 2002 Apr;128(4):177-81. Epub 2002 Feb 23. Review. Abstract Only.	
	C15	O'HAGAN et al., Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng. 2001 Oct 15;18(3):69-85. Review. Abstract Only.	
	C16	O'HAGAN et al., Recent developments in vaccine delivery systems. Curr Drug Targets Infect Disord. 2001 Nov;1(3):273-86. Review. Abstract Only.	
	C17	McCLUSKIE et al., Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants. Vaccine. 2001 Jun 14;19(27):3759-68.	
	C18	RAZ et al., Potential role of immunostimulatory DNA sequences (ISS) in genetic immunization and autoimmunity. American College of Rheumatology 60th National Scientific meeting and Association of Rheumatology Health Professional 31st National Scientific meeting, Orlando, Florida, October 18-22, 1996. Abstracts. Arthritis Rheum. 1996 Sep;39(9 Suppl): 615.	
	C19	SCHIRMBECK et al., Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells. J Immunol. 2003 Nov 15;171(10):5198-207.	
	C20	SINGH et al., Recent advances in veterinary vaccine adjuvants. Int J Parasitol. 2003 May;33(5-6):469-78. Review. Abstract Only.	
	C21	SINGH et al., Recent advances in vaccine adjuvants. Pharm Res. 2002 Jun;19(6):715-28. Review. Abstract Only.	
	C22	SINGH et al., Advances in vaccine adjuvants. Nat Biotechnol. 1999 Nov;17(11):1075-81. Review.	
	C23	SJOLANDER et al., Kinetics, localization and isotype profile of antibody responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. Scand J Immunol. 1996 Feb;43(2):164-72.	
	C24	SJOLANDER et al., Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses. Cell Immunol. 1997 Apr 10;177(1):69-76.	
▼	C25	ZHAO et al., Effect of different chemically modified oligodeoxynucleotides on immune stimulation. Biochem Pharmacol. 1996 Jan 26;51(2):173-82.	

EXAMINER:	DATE CONSIDERED: <i>or 10/10/05</i>
-----------	--

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]